BackTable Urology
Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay
Dr. Rana McKay
And then in the metastatic disease setting, you know, that's where we're really thinking about more continuous therapy with more lifelong hormonal therapy, though I think that many are beginning to challenge that paradigm a little bit. But more lifelong therapy and particularly for those individuals with high risk disease or de novo metastatic disease, adding an additional RSI.
0
💬
0
Comments
Log in to comment.
There are no comments yet.